Citation: | Ll Ying, YANG Bo, ZHANG Jing. The prognostic value of SII, NLR, PLR and LMR in the stage of ⅠA-ⅡA2 cervical cancer[J]. Chinese Journal of General Practice, 2021, 19(4): 554-557,576. doi: 10.16766/j.cnki.issn.1674-4152.001859 |
[1] |
WILD C P, WEⅡDERPASS E, STEWART B W. World cancer report: cancer research for cancer prevention[M]. Lyon: International Agency for Research on Cancer, 2020.
|
[2] |
HUANG H, LIU Q, ZHU L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer[J]. Sci Rep, 2019, 9(1): 87-108. doi: 10.1038/s41598-018-36442-9
|
[3] |
TEOH D G K, ISAKSSON V R, MONU M, et al. The predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in determining cervical cancer stage[J]. Gynecol Oncol, 2017, 145(3): 83. http://www.sciencedirect.com/science?_ob=ShoppingCartURL&_method=add&_eid=1-s2.0-S0090825817304110&originContentFamily=serial&_origin=article&_ts=1498985259&md5=e0eb81f6f3ccd574b01e6afb6d084274
|
[4] |
HAMILTON T, STEPHEN P D, JALAL H, et al. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT)[J]. Clinca Chimica Acta, 2020, 510(5): 711-716. http://www.sciencedirect.com/science/article/pii/S000989812030440X
|
[5] |
周晖, 刘昀昀, 罗铭, 等. 《2020 NCCN子宫颈癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2020, 36(2): 131-138. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF202002011.htm
|
[6] |
解秀珍. ⅠB-ⅡA期宫颈癌患者宫旁组织浸润的相关因素及腺癌与鳞癌的预后比较[D]. 济南: 山东大学, 2017.
|
[7] |
KAILASH N, MING Y L, SRINIVAS K-C, et al. Redistribution of cervix cancer patients from FIGO 2009 to FIGO 2018 staging following incorporation of medical imaging[J]. Int J Gynecol Cancer, 2019, 17(4): 1-8. http://www.researchgate.net/publication/336989640_Redistribution_of_Cervix_Cancer_Patients_from_FIGO_2009_to_FIGO_2018_Staging_Following_Incorporation_of_Medical_Imaging
|
[8] |
RICHA S, MOHAMMAD A, VARSHA S, et al. M2 polarization of macrophages by Oncostatin M in hypoxic tumor microenvironment is mediated by mTORC2 and promotes tumor growth and metastasis[J]. Cytokine, 2019, 118(6): 130-143. http://www.sciencedirect.com/science?_ob=ShoppingCartURL&_method=add&_eid=1-s2.0-S1043466618301182&originContentFamily=serial&_origin=article&_ts=1522773976&md5=5b2cc6f4c76375a499cc5439562552d4
|
[9] |
VITKAUSKAITE A, URBONIENE D, CELIESITUE J, et al. Circulating inflammatory markers in cervical cancer patients and healthy controls[J]. J Immunotoxicol, 2020, 17(1): 105-109. doi: 10.1080/1547691X.2020.1755397
|
[10] |
王金凤, 李琛, 黄康榕, 等. 术前中性粒细胞和淋巴细胞比值、单核细胞和淋巴细胞比值与宫颈癌患者临床病理特征的相关性[J]. 兰州大学学报(医学版), 2019, 45(5): 25-29. https://www.cnki.com.cn/Article/CJFDTOTAL-LZYX201905008.htm
|
[11] |
YUDA P, AGHA B, FIRDY L, et al. Pretreament neutrophi-to-lymphocyte ratio(NLR) and platelt-to-lymphocyte ratio(PLR) as a predicitive value of hematological markers in cervical cancer[J]. Asian Pac J Cancer Prew, 2019, 20(3), 863-868. doi: 10.31557/APJCP.2019.20.3.863
|
[12] |
ZHU M, FENG M, HE F, et al. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer[J]. Clinica Chimica Acta, 2018, 483(5): 296-302.
|
[13] |
CHEN L, ZHANG F, SHENG X, et al. Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: lymphocyte[J]. Medicine, 2016, 95(32): e4381. doi: 10.1097/MD.0000000000004381
|
[14] |
JI Y F, WANG H Y. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis[J]. World J Surg Oncol, 2020, 18(1): 847-860. http://www.researchgate.net/publication/343520941_Prognostic_prediction_of_systemic_immune-inflammation_index_for_patients_with_gynecological_and_breast_cancers_a_meta-analysis/download
|
[15] |
GAO Y, GUO W, CAI S, et al. Systemic immune-inflammation index (SⅡ) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma[J]. J Cancer, 2019, 10(14): 3188-3196. doi: 10.7150/jca.30281
|
[16] |
CHAO B, JU X, ZHANG L, et al. A novel prognostic marker systemic inflammation response index (SIRI) for operable cervical cancer patients[J]. Front Oncol, 2020, 10(1): 766. http://www.researchgate.net/publication/341348990_A_Novel_Prognostic_Marker_Systemic_Inflammation_Response_Index_SIRI_for_Operable_Cervical_Cancer_Patients
|
[17] |
HOLUB K, BIETE A. Impact of systemic inlammation biomarkers on the survival outcomes of cervical cancer patients[J]. Clin Transl Oncol, 2019, 21(7): 836-844. doi: 10.1007/s12094-018-1991-4
|
[18] |
WU J, CHEN M, LIANG C, et al. Prognostic value of the pretreament neutrophi-to-lymphocyte ratio in cervical cancer: A meta-analysis and systematic review[J]. Oncotarget, 2017, 8(8): 13400-13412. doi: 10.18632/oncotarget.14541
|
[19] |
KOZASA K, MABUCHI S, KOMURA N, et al. Comparison of clinical utilities of the platelet count and platelet-lymphocyte ratio for predicting survival in patients with cervical cancer: a single institutional study and literature review[J]. Oncotarget, 2017, 8(33): 55394-55404. doi: 10.18632/oncotarget.19560
|
[20] |
Paul D S, Trinh H, Hyder J, et al. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT)[J] Clinica Chimica Acta, 2020, 510(11): 711-716. http://www.sciencedirect.com/science/article/pii/S000989812030440X
|